Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial

Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hoersch D, Lapuerta P, Fleming R, Gross DJ (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Pancreas Lippincott, Williams & Wilkins

Book Volume: 47

Pages Range: 350-350

Journal Issue: 3

Involved external institutions

Charité - Universitätsmedizin Berlin

Germany (DE) Hospitales Universitarios Virgen Macarena y Virgen del Rocío

Spain (ES) Royal Victoria Infirmary

United Kingdom (GB) King's College Hospital (KCH)

United Kingdom (GB) Dana–Farber Cancer Institute

United States (USA) (US) University of Kentucky

United States (USA) (US) Stanford University

United States (USA) (US) Zentralklinikum Bad Berka

Germany (DE) Lexicon Pharmaceuticals, Inc.

United States (USA) (US) Hadassah Medical Center / מרכז רפואי הדסה‎‎

Israel (IL)

How to cite

APA:

Pavel, M., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R.R.P., Kulke, M.H.,... Gross, D.J. (2018). Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. (pp. 350-350).

MLA:

Pavel, Marianne, et al. "Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial." 2018. 350-350.

BibTeX: Download